News & Events

News &
Events

Dosing of first patient in Tarsius 2020 Phase I/IIa Clinical Study of TRS01

Feb. 25, 2020

TRS is a first-in-class investigational product for the treatment of blinding ocular diseases

TEL AVIV, Israel, February 25th, 2020 — Tarsius Pharma Ltd, a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases today announced the initiation of dosing in its Tarsius 2020 Trial.

This is a Multicenter, Double-Masked, Randomized, Vehicle-controlled, Dose-ranging Phase I/IIa Study to Evaluate the Safety of TRS01 Eye Drops in Participants with Post-surgical Inflammation.

The first patient was dosed on February 7th, 2020 and as of today, 3 patients completed the treatment time-frame, and additional patients are already enrolled in the USA. The trial is expected to enroll approximately 60 patients with Post-cataract inflammation and top-line results from this trial are expected by mid-2020.

Dr Daphne Haim-Langford, Tarsius’ Founder and CEO, stated, “We are excited to enter the clinical development journey with this randomized controlled study. Translating our promising preclinical data with TRS01 to treatment of patients is an important milestone.”

“We are thankful to all Tarsius’ partners that are working together with us on this project to make this happen, and hope for a timely patient recruitment by the professional and experienced principal investigators selected for this study”, stated Zohar Milman, Tarsius’ COO.

About Ocular Inflammatory Diseases

Ocular inflammatory diseases impose a significant medical and economic burden on society, affecting hundreds of million people worldwide and posing severe risks of vision loss and blindness.

In more than 50 years, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in life-changing consequences.

The TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases.

About the Company

Tarsius Pharma was established in 2016 and is focused on developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases.

The company’s investors include Sun Pharmaceuticals, a global pharmaceutical company, BioLight Life Sciences Ltd, as well as private investors and family offices. This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 879598.  

For more information please contact:
info@tarsiuspharma.com
Tel: +1-914-3392556
http://www.tarsiuspharma.com

Scroll to Top Skip to content